All practice questions

Question 4121Question →

A pharmaceutical representative presents a promotional brochure and a summary of the methodology for a recent clinical trial evaluating a novel lipid-lowering medication. As the evaluating physician, you must critically appraise the claims and study design. Match each excerpt from the promotional material or trial methodology with the biostatistical concept or potential bias it best exemplifies.

Click a left item, then click its matching right item

Show answer & explanation

Answer

The correct matches map the trial's methodology and promotional claims to their respective epidemiological concepts: evaluating adherent patients only represents a per-protocol analysis, highlighting the proportional

40\%

drop represents relative risk reduction, halting the trial early introduces early stopping bias, and differential follow-up introduces performance bias.

Each excerpt from the clinical trial methodology and drug advertisement maps to a specific biostatistical principle or bias that physicians must recognize when appraising medical literature. Understanding the differences between per-protocol and intention-to-treat analysis, relative versus absolute risk reduction, and forms of bias is critical for accurate evaluation.

Step-by-Step Solution

1

Analyze the first excerpt regarding patient adherence and efficacy calculation.

Identified as a per-protocol analysis.

Excluding non-adherent patients evaluates drug efficacy under ideal conditions rather than real-world effectiveness, violating the intention-to-treat principle.

2

Analyze the second excerpt calculating the

40\%

risk reduction.

Identified as relative risk reduction.

The absolute drop is

2\%

(

5\%

to

3\%

), but the proportional drop relative to the baseline (

2\%

/

5\%

) equals

40\%

, which is a common drug advertisement tactic.

3

Analyze the third excerpt regarding halting the study at

12

months instead of

36

months.

Identified as early stopping bias.

Stopping a trial early at a random statistical 'high' often overestimates the true sustained benefit of the medication.

4

Analyze the fourth excerpt regarding differential monitoring and counseling.

Identified as performance bias.

Unequal provision of care or co-interventions between groups distorts the attribution of the outcome solely to the study drug.

Key Concept

Medical Literature and Drug Advertisement Interpretation

Question 4122Question →

Epidemiologists are designing an observational cohort study to explore the relationship between frequent consumption of ultra-processed foods and the incidence of chronic kidney disease (CKD) in adults over age 50. The investigators recognize that preexisting hypertension is strongly associated with both poor dietary habits and an increased risk of CKD. They are concerned that this variable could distort the true association between the dietary exposure and the outcome.

Which of the following strategies are valid methodological or statistical approaches to control for this specific variable? (Select all that apply)

Select all that apply

Restricting study enrollment exclusively to participants without a baseline history of hypertension

Including hypertension as an independent covariate in a multivariable regression model during data analysis

Utilizing an intention-to-treat framework to manage participants who alter their dietary habits during the follow-up period

Calculating a pooled, adjusted risk estimate even if the relative risk of CKD significantly differs between hypertensive and normotensive strata

Determining the positive predictive value of the dietary assessment tool to ensure it accurately identifies at-risk individuals

Show answer & explanation

Answer: Restricting study enrollment exclusively to participants without a baseline history of hypertension; Including hypertension as an independent covariate in a multivariable regression model during data analysis

Answer

The correct approaches to control for confounding in this scenario are restricting the study population to individuals without hypertension and adjusting for hypertension using a multivariable regression model.

Confounding occurs when an extraneous variable is associated with both the exposure and the outcome, distorting their true relationship. This distortion can be controlled during the study design phase through restriction (e.g., only enrolling normotensive individuals), which prevents the confounder from varying within the study population. Alternatively, during the data analysis phase, confounding can be controlled by including the variable as a covariate in a multivariable regression model, which mathematically adjusts the exposure-outcome association for the influence of the confounder.

Step-by-Step Solution

1

Identify the methodological problem described in the scenario.

The scenario describes hypertension as a potential confounder because it is associated with both the exposure (ultra-processed diet) and the outcome (CKD).

Recognizing the epidemiological role of the variable is required to select appropriate statistical and methodological control strategies.

2

Evaluate each option as a valid method to control for confounding in either the design or analysis phase.

Restriction (a design-phase method) and multivariable regression (an analysis-phase method) are recognized and valid methods to effectively control for confounding.

Restriction eliminates confounding by ensuring all subjects have the same baseline level of the confounder. Regression mathematically adjusts for the confounder's effect during data analysis.

3

Identify why the remaining options are incorrect epidemiological approaches for this specific problem.

Intention-to-treat is used for preserving randomization in trials, pooling heterogeneous strata ignores effect modification, and positive predictive value evaluates diagnostic tests.

These techniques serve entirely different statistical purposes and do not mitigate the distortion caused by confounding variables.

Key Concept

Methods for controlling confounding variables in observational studies (e.g., Restriction, Matching, Stratification, Multivariable Regression).

Question 4123Question →

Researchers frequently encounter methodological challenges that threaten the validity of their findings. Evaluate the following study design flaws or unexpected clinical trial phenomena and match each specific scenario with the epidemiological concept that best describes the underlying threat to validity.

Click a left item, then click its matching right item

Show answer & explanation

Answer

The correct pairings identify observer bias (unblinded investigator influences outcome), confounding (vanishes after adjustment for smoking), the Hawthorne effect (behavior changes due to being monitored), confounding by indication (baseline health dictates treatment assignment), and lead-time bias (earlier detection increases apparent survival time without mortality benefit).

Each pairing is correct based on foundational biostatistical definitions: observer bias stems from the researcher, the Hawthorne effect stems from the subject, confounding involves a third linked variable, confounding by indication is treatment assignment based on prognosis, and lead-time bias is an artifact of early screening.

Step-by-Step Solution

1

Analyze each study scenario to identify the primary mechanism distorting the measured outcome.

Isolated the specific methodological flaw in each stem (e.g., lack of blinding, extraneous variables, observation-driven behavior change).

Each bias or validity threat has a unique signature in how it alters epidemiological data.

2

Match the identified flaw with standard epidemiological terminology.

Paired the scenarios precisely with observer bias, confounding, the Hawthorne effect, confounding by indication, and lead-time bias.

Accurate categorization dictates the appropriate method required to mitigate the threat in future studies.

Key Concept

Internal validity is frequently threatened by specific biases and confounding factors that must be recognized and mitigated through rigorous study design (blinding, randomization, control groups) and statistical adjustment.

Question 4124Question →

A hospitalist is reviewing an article from a leading medical journal detailing a phase 3, randomized, double-blind trial. The study evaluated the efficacy and safety of a novel factor XIa inhibitor compared to a placebo for preventing recurrent venous thromboembolism (VTE) in patients with high-risk thrombophilia. A total of 5,200 patients were randomized in a 1:1 ratio to receive either the novel medication or a placebo. The trial summary table is presented below.

Endpoint	Placebo (n=2,600)	Novel Inhibitor (n=2,600)	p-value
Primary Efficacy (Recurrent VTE or VTE-related death)	286 (11.0%)	156 (6.0%)	<0.001
Primary Safety (Major bleeding)	39 (1.5%)	65 (2.5%)	0.012

Based on the study results, what is the number needed to treat (NNT) to prevent one primary efficacy endpoint event? (Provide the exact whole number.)

Show answer & explanation

Answer: 20

Answer

20

The Number Needed to Treat (NNT) is calculated as the inverse of the Absolute Risk Reduction (ARR). The primary efficacy endpoint occurred in 11.0% of the placebo group (CER =

0.11

) and 6.0% of the novel inhibitor group (EER =

0.06

). The ARR is

0.11 - 0.06 = 0.05

. Therefore, the NNT is

\frac{1}{0.05} = 20

. This means 20 patients must be treated with the novel factor XIa inhibitor to prevent one recurrent VTE or VTE-related death.

Step-by-Step Solution

1

Identify the event rates for the primary efficacy endpoint from the provided table.

Control Event Rate (CER) = 11.0% (

0.11

); Experimental Event Rate (EER) = 6.0% (

0.06

).

Calculating the number needed to treat requires the exact incidence rates of the primary outcome in both the control and treatment groups.

2

Calculate the Absolute Risk Reduction (ARR).

ARR = 0.11 - 0.06 = 0.05

ARR represents the absolute difference in the risk of the outcome between the placebo group and the active treatment group.

3

Calculate the Number Needed to Treat (NNT).

NNT = \frac{1}{ARR} = \frac{1}{0.05} = 20

The NNT is defined as the inverse of the Absolute Risk Reduction. It indicates how many patients must be treated to prevent one adverse outcome.

Key Concept

Number Needed to Treat (NNT) Calculation

Question 4125Question →

A medical team reviews a population-based case-control study investigating the association between a newly developed oral immunomodulator and the risk of developing drug-induced lupus erythematosus (DILE). The initial unadjusted analysis yields an odds ratio (OR) of 3.2 (95% CI: 2.4 - 4.1), suggesting a significant association. Recognizing that drug metabolism rates vary in the population, the researchers decide to stratify the study data based on the patients' hepatic acetylator phenotype. Upon re-analysis, the OR for developing DILE in the subgroup of slow acetylators is 6.1 (95% CI: 4.2 - 8.5). In contrast, the OR in the subgroup of rapid acetylators is 1.1 (95% CI: 0.7 - 1.5). Which of the following epidemiological concepts best explains the role of the acetylator phenotype in these findings?

Confounding

Effect modification

Selection bias

Measurement bias

Lead-time bias

Show answer & explanation

Answer: Effect modification

Answer

Effect modification

The correct answer is effect modification because the magnitude of the association between the immunomodulator and the development of DILE is vastly different across the strata of the third variable (acetylator phenotype). Slow acetylators have a strong association (OR = 6.1), whereas rapid acetylators have no significant association (OR = 1.1). This biological interaction is a natural phenomenon that should be reported, rather than a methodological flaw to be adjusted for.

Step-by-Step Solution

1

Analyze the initial unadjusted findings of the study.

The crude odds ratio is 3.2, indicating an overall positive association between the immunomodulator and DILE.

Establishing the baseline relationship is necessary before interpreting the effects of stratification.

2

Evaluate the data after stratification by the third variable (acetylator phenotype).

The stratum-specific OR is 6.1 for slow acetylators and 1.1 for rapid acetylators.

Stratification reveals whether the third variable alters the primary association or merely distorts it.

3

Compare the stratum-specific odds ratios to each other.

The stratum-specific ORs (6.1 and 1.1) are significantly different from one another.

When stratum-specific measures differ significantly from each other, it defines effect modification (a true biological interaction) rather than confounding.

Key Concept

Effect modification occurs when the magnitude of an exposure-disease association differs significantly depending on the level of a third variable. It is identified during stratified analysis when the stratum-specific measures of association are distinct from one another.

Question 4126Question →

A physician is reviewing a promotional pamphlet for a newly approved oral hypoglycemic agent. The pamphlet includes a safety summary comparing the incidence of severe hypoglycemic episodes between the new medication and placebo over a 52-week clinical trial period.

The safety data excerpt reports the following:
- Novel Agent Group ( $N = 4,000$ ): 180 patients experienced at least one episode of severe hypoglycemia.
- Placebo Group ( $N = 4,000$ ): 112 patients experienced at least one episode of severe hypoglycemia.

Based on the clinical trial data provided in the promotional material, how many patients must be treated with the novel agent instead of placebo for 52 weeks to expect one additional severe hypoglycemic event? (Round your final answer to the nearest whole number).

Show answer & explanation

Answer: 59

Answer

59

The Number Needed to Harm (NNH) is derived from the Absolute Risk Increase (ARI). The ARI is the difference between the Experimental Event Rate (EER) and the Control Event Rate (CER). In this trial, the EER is

180/4000 = 0.045

and the CER is

112/4000 = 0.028

. The difference (ARI) is

0.017

. The NNH is calculated by taking the reciprocal of the ARI (

1/0.017

), which equals

58.82

. Rounding to the nearest whole number yields

59

patients.

Step-by-Step Solution

1

Calculate the Experimental Event Rate (EER).

EER = \frac{180}{4000} = 0.045

(or

4.5\%

)

To determine the absolute risk of the adverse event in the population receiving the new intervention.

2

Calculate the Control Event Rate (CER).

CER = \frac{112}{4000} = 0.028

(or

2.8\%

)

To determine the baseline absolute risk of the adverse event in the control population.

3

Calculate the Absolute Risk Increase (ARI).

ARI = EER - CER = 0.045 - 0.028 = 0.017

(or

1.7\%

)

To find the excess risk of the adverse event directly attributable to the new medication.

4

Calculate the Number Needed to Harm (NNH).

NNH = \frac{1}{ARI} = \frac{1}{0.017} \approx 58.82

NNH indicates how many patients need to be exposed to the risk factor over a specific period to cause one additional harmful event.

5

Round the final value to the nearest whole number.

59

Clinical metrics representing whole patients cannot be expressed as fractions, and standard rounding rules apply.

Key Concept

The Number Needed to Harm (NNH) quantifies the safety of an intervention and is calculated as the inverse of the Absolute Risk Increase (

NNH = 1 / ARI

).

Question 4127Question →

A healthcare system's pharmacy and therapeutics committee is reviewing a recently published multi-center, randomized, double-blind, placebo-controlled trial. The trial evaluated the efficacy and safety of a novel oral anticoagulant for stroke prevention in patients with non-valvular atrial fibrillation. The committee is determining whether to add this medication to their preferred formulary. The trial followed participants for a median of $2$ years. A summary table from the publication is provided below:

Clinical Endpoint	Novel Drug ( $n=5,000$ )	Placebo ( $n=5,000$ )	Hazard Ratio ( $95\%$ CI)
Ischemic Stroke	$150$ ( $3.0\%$ )	$250$ ( $5.0\%$ )	$0.59$ ( $0.45-0.78$ )
Major Gastrointestinal Bleeding	$200$ ( $4.0\%$ )	$50$ ( $1.0\%$ )	$4.08$ ( $2.55-6.52$ )
All-cause Mortality	$400$ ( $8.0\%$ )	$420$ ( $8.4\%$ )	$0.95$ ( $0.80-1.12$ )

The chief medical officer requests a population-level impact analysis. If the healthcare system immediately switches $2,500$ similar patients from placebo to the novel drug, which of the following is the most accurate projected clinical impact over a $2$ -year period based on these trial results?

Prevention of

50

ischemic strokes and an increase of

75

major gastrointestinal bleeding events

Prevention of

50

ischemic strokes and a statistically significant reduction in all-cause mortality

The reduction in ischemic strokes is entirely explained by confounding, as the overall mortality rate did not improve

The positive predictive value of the drug is nullified because the absolute risk increase for bleeding exceeds the absolute risk reduction for stroke

The drug is absolutely contraindicated in this population due to the

300\%

relative risk increase in major gastrointestinal bleeding

Show answer & explanation

Answer: Prevention of $50$ ischemic strokes and an increase of $75$ major gastrointestinal bleeding events

Answer

Prevention of 50 ischemic strokes and an increase of 75 major gastrointestinal bleeding events

The correct answer accurately calculates the absolute population impact using the raw event rates provided in the table. The Absolute Risk Reduction (ARR) for ischemic stroke is

5.0\% - 3.0\% = 2.0\%

. Over

2,500

patients, this prevents

50

strokes (

2,500 \times 0.02

). The Absolute Risk Increase (ARI) for major gastrointestinal bleeding is

4.0\% - 1.0\% = 3.0\%

. Over

2,500

patients, this causes

75

additional bleeding events (

2,500 \times 0.03

). Translating relative metrics (like Hazard Ratios) into absolute numbers is essential for population health management and shared decision-making.

Step-by-Step Solution

1

Calculate the Absolute Risk Reduction (ARR) for the primary efficacy endpoint (Ischemic Stroke).

\text{ARR} = \text{Placebo Rate} - \text{Drug Rate} = 5.0\% - 3.0\% = 2.0\%

(or

0.02

).

ARR determines the actual absolute percentage of patients spared from the adverse outcome when treated.

2

Apply the ARR to the target population of 2,500 patients to find the number of strokes prevented.

2,500 \times 0.02 = 50

ischemic strokes prevented.

Multiplying the ARR by the number of treated patients yields the projected population benefit.

3

Calculate the Absolute Risk Increase (ARI) for the primary safety endpoint (Major Gastrointestinal Bleeding).

\text{ARI} = \text{Drug Rate} - \text{Placebo Rate} = 4.0\% - 1.0\% = 3.0\%

(or

0.03

).

ARI determines the actual absolute percentage of patients who will suffer the adverse effect due to the treatment.

4

Apply the ARI to the target population of 2,500 patients to find the number of additional bleeds.

2,500 \times 0.03 = 75

additional major gastrointestinal bleeding events.

Multiplying the ARI by the number of treated patients yields the projected population harm.

Key Concept

Evaluating clinical impact requires calculating Absolute Risk Reduction (ARR) and Absolute Risk Increase (ARI) from trial event rates and applying them directly to the proposed population size.

Question 4128Question →

A state public health department reviews a retrospective cohort study evaluating a newly approved inhaled pulmonary vasodilator for the prevention of recurrent exacerbations in patients with severe chronic obstructive pulmonary disease (COPD). The primary analysis reports a crude relative risk (RR) of $1.62$ (95% CI: $1.35-1.94$ ) for recurrent exacerbations in patients using the new vasodilator compared to those on standard therapy. Concerned that concurrent active smoking might influence the outcomes, researchers perform a stratified analysis based on smoking status. In the stratum of active smokers, the RR is $2.85$ (95% CI: $2.10-3.88$ ). In the stratum of non-smokers, the RR is $1.05$ (95% CI: $0.88-1.25$ ). Based on these findings, which of the following best describes the role of active smoking in this study?

It acts as an effect modifier, indicating that the magnitude of the drug's effect differs depending on smoking status.

It acts as a confounding variable, indicating that smoking distorts the true overall association between the drug and exacerbations.

It represents a Hawthorne effect, suggesting that participants altered their smoking habits due to study observation.

It introduces selection bias, indicating that smokers and non-smokers were unequally distributed between treatment groups.

It invalidates the calculated relative risks, requiring the use of an independent t-test for categorical data comparison.

Show answer & explanation

Answer: It acts as an effect modifier, indicating that the magnitude of the drug's effect differs depending on smoking status.

Answer

It acts as an effect modifier, indicating that the magnitude of the drug's effect differs depending on smoking status.

The scenario describes a classic presentation of effect modification. Effect modification occurs when a third variable (in this case, active smoking) changes the magnitude of the association between the exposure (pulmonary vasodilator) and the outcome (COPD exacerbations). This is identified statistically through stratified analysis: if the stratum-specific relative risks are significantly different from one another (

2.85

vs.

1.05

), the third variable is an effect modifier. In such cases, it is inappropriate to report the crude relative risk alone; instead, the results should be reported separately for each stratum.

Step-by-Step Solution

1

Identify the study design and the reported statistical measures.

The study is a retrospective cohort study reporting a crude relative risk of

1.62

.

Establishing the baseline measurement of association before stratification is necessary to compare results.

2

Examine the results of the stratified analysis based on the third variable (active smoking).

The relative risk is

2.85

for active smokers and

1.05

for non-smokers.

Stratification is the primary method used to distinguish between confounding and effect modification in epidemiology.

3

Compare the stratum-specific relative risks to each other.

The stratum-specific relative risks (

2.85

and

1.05

) are substantially different from each other, and their confidence intervals do not overlap.

When stratum-specific estimates differ significantly from one another, the third variable is modifying the biological or clinical effect of the exposure, confirming effect modification.

Key Concept

Effect modification occurs when the magnitude or direction of an association between an exposure and an outcome varies according to the level of a third variable. It is identified when stratum-specific measures of association differ significantly from each other.

Question 4129Question →

A medical resident is evaluating a newly published phase 3, randomized, controlled trial comparing a novel immunomodulator to standard therapy for the treatment of refractory plaque psoriasis. The resident is reviewing the methodology and results sections to present at the weekly journal club. The trial's patient enrollment and allocation are depicted in the accompanying CONSORT flow diagram. Match each excerpted statement from the publication to the corresponding methodological concept or principle it best represents.

Click a left item, then click its matching right item

Show answer & explanation

Answer

Excerpt 1 matches with Intention-to-treat analysis. Excerpt 2 matches with Establishment of non-inferiority. Excerpt 3 matches with High risk of attrition bias. Excerpt 4 matches with Limited external validity (generalizability).

Proper interpretation of medical literature requires accurately identifying study design features and potential biases. Analyzing patients in their original randomized groups represents an intention-to-treat analysis, which preserves randomization benefits. When a trial's confidence interval for the treatment difference safely excludes the pre-specified margin, non-inferiority is established. Differential loss to follow-up creates attrition bias, threatening internal validity. Finally, strict exclusion criteria that eliminate typical, complex patients reduce the study's external validity (generalizability).

Step-by-Step Solution

1

Analyze the first excerpt regarding data analysis of all randomized subjects.

The phrase 'analyzed according to their initially assigned treatment group' indicates an intention-to-treat (ITT) analysis.

ITT is a fundamental biostatistical principle designed to prevent bias caused by the loss of participants, maintaining the prognostic balance generated by original randomization.

2

Evaluate the second excerpt detailing a 95% confidence interval and a pre-defined margin.

This describes the criteria for the establishment of non-inferiority.

When a confidence interval's boundary does not cross a pre-specified margin of clinical significance, the novel intervention is deemed statistically non-inferior to the active control.

3

Examine the third excerpt about unequal loss to follow-up between study arms.

Differential dropout rates due to side effects point to a high risk of attrition bias.

If the patients dropping out differ systematically from those who remain, the study's internal validity is compromised, which is the hallmark of attrition bias.

4

Assess the final excerpt describing strict exclusion criteria for common comorbidities.

Excluding representative patients leads to limited external validity.

External validity refers to how well study results can be generalized to everyday practice; omitting common patient phenotypes severely limits this.

Key Concept

Evaluation of clinical trial methodology, including intention-to-treat principles, non-inferiority design, internal validity threats, and external validity.

Estimated Time:1m 30s

Question 4130Question →

A medical investigation team is conducting a retrospective cohort study to evaluate the risk of acute kidney injury (AKI) associated with a newly introduced intravenous antimicrobial agent compared to a standard treatment regimen. The investigators suspect that pre-existing chronic kidney disease (CKD) might distort the primary association. To investigate this, they perform a stratified analysis based on baseline CKD status.

The results yield a crude relative risk (RR) of 2.8 for AKI in the new antimicrobial group. However, the stratum-specific RR for patients with baseline CKD is 1.1, and the RR for patients without baseline CKD is 1.2. The Mantel-Haenszel adjusted RR is calculated to be 1.15.

Based on these findings, which of the following statements are correct regarding the statistical interpretation and methodological handling of this variable? (Select all that apply)

Select all that apply

The data demonstrates that baseline renal status is a confounding factor rather than an effect modifier.

Restricting study enrollment solely to patients without pre-existing renal impairment is a valid design-phase method to prevent this specific statistical issue.

The statistical findings suggest that the new antimicrobial agent synergistically interacts with pre-existing renal disease to increase toxicity.

The crude risk estimate should be reported as the primary finding because statistical adjustment artificially dilutes the true clinical effect.

Stratification reveals that the drug's nephrotoxic impact is significantly more pronounced in the subgroup with compromised baseline renal function.

Show answer & explanation

Answer: The data demonstrates that baseline renal status is a confounding factor rather than an effect modifier.; Restricting study enrollment solely to patients without pre-existing renal impairment is a valid design-phase method to prevent this specific statistical issue.

Answer

The correct statements are that the data demonstrates confounding rather than effect modification, and that restricting study enrollment is a valid design-phase method to prevent this issue.

The scenario presents classic criteria for confounding: a significant discrepancy between the crude risk estimate and the adjusted/stratum-specific estimates, while the stratum-specific estimates remain similar to one another. Once identified as a confounder, standard epidemiological methods can be applied for control. Restricting the study to a single stratum (e.g., only enrolling patients without pre-existing renal impairment) is a highly effective design-stage method to eliminate the confounding effect of that variable.

Step-by-Step Solution

1

Analyze the relationship between the crude relative risk and the stratum-specific relative risks.

The crude RR is 2.8, while the stratum-specific RRs are 1.1 and 1.2. The adjusted RR is 1.15.

Comparing crude to stratum-specific estimates is the standard method for differentiating confounding from effect modification.

2

Determine if the variable is a confounder or an effect modifier based on the analysis.

Because the stratum-specific RRs (1.1 and 1.2) are similar to each other and to the adjusted RR (1.15), but significantly different from the crude RR (2.8), the variable is a confounder.

Confounding distorts the overall (crude) association, which is corrected upon stratification. Effect modification occurs when the magnitude of the effect differs across strata.

3

Evaluate potential methods for controlling the identified statistical issue.

Since the issue is confounding, appropriate control methods include design-phase strategies (randomization, matching, restriction) and analysis-phase strategies (stratification, multivariable regression).

Identifying the correct mitigation strategies requires matching the statistical issue (confounding) with valid epidemiological tools. Restriction (excluding CKD patients) correctly addresses confounding during the design phase.

Key Concept

Confounding vs. Effect Modification and Methods of Control

Question 4131Question →

A family physician is reviewing a promotional brochure for a newly approved oral anti-obesity medication. The brochure prominently features a bar chart demonstrating a " $25\%$ reduction in total body weight at $12$ months" ( $p < 0.001$ ) compared to placebo.

Upon reading the methodology section in the fine print, the physician notes that the randomized controlled trial initially enrolled $2,000$ participants ( $1,000$ in the treatment arm and $1,000$ in the placebo arm). However, the final efficacy analysis only included the $400$ patients in the treatment arm and $600$ patients in the placebo arm who completed all scheduled clinic visits over the $12$ -month period. The text states that the majority of participants who did not complete the study in the treatment arm withdrew early due to intolerable gastrointestinal side effects.

Based on the trial's methodology, which of the following best describes the primary threat to the validity of the advertisement's efficacy claim?

The primary flaw is the failure to use a Chi-square test to appropriately adjust for the participants who withdrew from the study.

The efficacy claim is likely overestimated due to attrition bias, as the analysis excluded patients who could not tolerate the medication.

The unequal dropout rate between the two arms artificially decreases the positive predictive value of the primary endpoint.

The researchers committed premature closure by analyzing the data at

12

months rather than waiting for long-term cardiovascular outcomes.

The high rate of gastrointestinal side effects establishes an absolute contraindication, invalidating the statistical significance of the weight loss.

Show answer & explanation

Answer: The efficacy claim is likely overestimated due to attrition bias, as the analysis excluded patients who could not tolerate the medication.

Answer

The efficacy claim is likely overestimated due to attrition bias, as the analysis excluded patients who could not tolerate the medication.

The trial exhibits a severe case of attrition bias (loss to follow-up bias). In randomized controlled trials, if a significant number of participants drop out, and especially if the dropout rates differ between the treatment and placebo arms (differential attrition), the remaining participants may no longer be representative of the original randomized groups. The advertisement bases its

25\%

weight loss claim on a 'per-protocol' analysis (only those who completed the study). Because

60\%

of the treatment arm dropped out largely due to adverse effects, those who remained were likely the ones who tolerated the drug best and potentially had the best outcomes. This violates the principle of randomization and artificially inflates the drug's apparent efficacy. An intention-to-treat (ITT) analysis, which includes all patients originally randomized regardless of completion, is the standard for avoiding this bias.

Step-by-Step Solution

1

Analyze the trial's enrollment and completion numbers.

The trial enrolled

2,000

patients but only analyzed

1,000

(

400

in treatment,

600

in placebo). This represents a massive

50\%

overall dropout rate, with disproportionate dropouts in the treatment arm (

60\%

vs

40\%

).

To identify discrepancies between the enrolled population and the analyzed population.

2

Determine the type of analysis used by the researchers.

By only analyzing patients who completed all clinic visits, the researchers utilized a 'per-protocol' analysis rather than an 'intention-to-treat' (ITT) analysis.

To understand how the missing data was handled statistically.

3

Identify the epidemiological bias introduced by this methodology.

The exclusion of dropouts, especially those who left due to adverse effects, introduces attrition bias. This selectively removes patients who likely failed the therapy, leading to an overestimation of the drug's true efficacy in a real-world setting.

To evaluate the validity of the advertisement's clinical claims.

Key Concept

Identifying attrition bias and the importance of Intention-To-Treat (ITT) analysis in randomized controlled trials.

Estimated Time:1m 30s

Question 4132Question →

Clinical researchers design a randomized trial comparing a novel topical calcineurin inhibitor to standard high-potency topical corticosteroids in patients with severe atopic dermatitis. The primary outcome is achieving a 75% reduction in the Eczema Area and Severity Index (EASI-75) at 12 weeks.

The crude analysis of the entire study cohort shows no statistically significant difference in achieving the primary outcome between the two interventions (Relative Risk [RR] = 1.05, 95% CI: 0.92-1.19).

To investigate further, the research team performs a stratified analysis based on the presence of a null mutation in the filaggrin ( $FLG$ ) gene.

Among subjects harboring the $FLG$ mutation, the RR for achieving EASI-75 with the novel inhibitor versus corticosteroids is 1.65 (95% CI: 1.40-1.95).

Among subjects lacking the $FLG$ mutation, the corresponding RR is 0.85 (95% CI: 0.75-0.96).

Based on these stratified statistical findings, which of the following terms best describes the role of the $FLG$ mutation in this clinical trial?

Effect modifier

Confounding variable

Determinant of positive predictive value

Categorical dependent variable

Source of anchoring bias

Show answer & explanation

Answer: Effect modifier

Answer

Effect modifier

The correct answer is effect modifier. Effect modification (or interaction) occurs when the magnitude or direction of an exposure's effect on an outcome varies significantly depending on the level of a third variable. In this scenario, the initial crude analysis showed no significant difference between the treatments (RR = 1.05). However, stratification revealed a significant benefit for the novel inhibitor in patients with the mutation (RR = 1.65), and a significant benefit for corticosteroids in patients without the mutation (RR = 0.85). Because the treatment's efficacy fundamentally depends on the patient's genetic status, the

FLG

mutation acts as an effect modifier. This represents a genuine biological interaction rather than an error or distortion in the study design.

Step-by-Step Solution

1

Evaluate the crude (unstratified) relative risk provided in the study.

The crude RR is 1.05 (95% CI: 0.92-1.19), which is not statistically significant, suggesting no overall difference in efficacy between the two treatments.

Establishing the baseline finding is necessary to understand the impact of subsequent stratification.

2

Analyze the stratum-specific relative risks after dividing the population by the third variable (

FLG

mutation).

The RR is 1.65 in patients with the mutation (favoring the novel inhibitor) and 0.85 in patients without the mutation (favoring corticosteroids).

Comparing strata identifies how the third variable influences the association between exposure and outcome.

3

Compare the stratum-specific relative risks to each other and to the crude relative risk.

The stratum-specific RRs are significantly different from each other and point in opposite therapeutic directions, while the crude RR is an average of the two.

This specific statistical pattern—where strata show vastly different effects—is the hallmark of effect modification, differentiating it from confounding.

Key Concept

Effect modification is present when the effect of an exposure on an outcome is altered by the presence of a third variable, indicated by stratum-specific measures of association that are significantly different from one another.

Question 4133Question →

Match each clinical research scenario with the specific type of epidemiological bias or methodological flaw it best represents.

Click a left item, then click its matching right item

Show answer & explanation

Answer

The correct matches map the glucose monitor scenario to the Hawthorne effect, the valvular surgery triage to Confounding by indication, the physical therapy dropouts to Attrition bias, and the unblinded interviewers to Observer-expectancy bias.

Each scenario perfectly illustrates the mechanistic definition of its corresponding bias. The Hawthorne effect is subject-driven. Confounding by indication is driven by clinical triage logic in observational data. Attrition bias is driven by differential dropout. Observer-expectancy bias is researcher-driven due to lack of blinding.

Step-by-Step Solution

1

Analyze the glucose monitor scenario

Subjects altered their behavior because they were being studied.

This is the classic definition of the Hawthorne effect, where observation itself changes the measured outcome.

2

Analyze the valvular surgery scenario

The treatment choice was driven by disease severity, making the surgery group inherently sicker.

This represents confounding by indication, a common issue in observational studies where treatment allocation is non-random.

3

Analyze the physical therapy scenario

Patients with worse pain dropped out and were excluded from analysis.

The differential loss to follow-up based on the outcome of interest defines attrition bias, falsely inflating the perceived efficacy of the therapy.

4

Analyze the depression interview scenario

Unblinded researchers scored patients differently based on their treatment assignment.

When a researcher's expectations influence subjective measurements, it is termed observer-expectancy bias (or Pygmalion effect).

Key Concept

Recognition of specific epidemiological biases and confounding variables in clinical research scenarios.

Question 4134Question →

During a monthly departmental conference, a cardiology fellow presents data on a novel direct oral anticoagulant used for stroke prevention in atrial fibrillation. The fellow displays a summary slide provided by the drug's manufacturer, which highlights a relative risk (RR) of $0.45$ ( $95\%$ CI: $0.38 - 0.53$ , $p < 0.01$ ) for major gastrointestinal bleeding when compared to standard warfarin therapy. The data is derived from a recently published retrospective cohort study of $2,400$ patients.

A faculty member questions the validity of the manufacturer's bold safety claim and projects the study's unadjusted baseline characteristics table for the audience:

Characteristic	Novel DOAC ( $n=1200$ )	Warfarin ( $n=1200$ )
Mean Age (years)	$62$	$79$
GFR $< 30 \text{ mL/min}$	$11\%$	$46\%$
History of Peptic Ulcer	$2\%$	$9\%$

The faculty member notes that the reported relative risk was calculated directly from the raw event rates without any multivariable regression or propensity score matching.

Which of the following is the most accurate epidemiological critique of the safety claim presented on the manufacturer's slide?

The apparent safety benefit is primarily driven by confounding by indication rather than true drug superiority.

The baseline demographic differences represent effect modification, which inherently invalidates the unadjusted relative risk.

The relative risk is an invalid metric here because the positive predictive value of bleeding depends on population prevalence.

The analysis utilized an inappropriate inferential statistical test for evaluating categorical adverse events across two cohorts.

The outcome disparity simply reflects expected pharmacokinetic differences in the intrinsic versus extrinsic coagulation cascades.

Show answer & explanation

Answer: The apparent safety benefit is primarily driven by confounding by indication rather than true drug superiority.

Answer

The apparent safety benefit is primarily driven by confounding by indication rather than true drug superiority.

The correct answer correctly identifies that the baseline imbalances in age and comorbidities act as confounders. In observational studies, physicians do not assign medications randomly; they prescribe based on patient characteristics. Here, sicker and older patients were preferentially given warfarin (likely due to provider familiarity or specific guidelines for advanced renal disease). Because older age and poor renal function independently increase bleeding risk, the unadjusted relative risk makes the novel drug look much safer than it actually might be. This phenomenon is known as confounding by indication.

Step-by-Step Solution

1

Analyze the study design and the data provided in the stem.

The study is a retrospective cohort study without multivariable adjustment. The table shows massive differences in baseline risk factors (age, renal function, ulcer history) between the two groups.

Identifying the study type and baseline differences is crucial for evaluating the validity of the reported outcomes.

2

Evaluate the impact of the baseline characteristics on the outcome.

The warfarin group is significantly older, has worse renal function, and has a higher history of peptic ulcers. All of these independently increase the risk of the primary outcome (gastrointestinal bleeding).

If the baseline risk of bleeding is already much higher in the warfarin group, a higher incidence of bleeding in that group cannot be reliably attributed to the drug itself.

3

Synthesize the methodological flaw.

Because providers likely chose warfarin for sicker patients based on established familiarity, the indication for the specific drug choice is linked to the outcome. This is classic confounding by indication.

Observational studies without matching or regression cannot account for non-randomized treatment allocation, invalidating raw efficacy or safety claims.

Key Concept

Confounding by indication in observational studies

Alternative Method

Whenever evaluating a pharmaceutical advertisement based on an observational study, immediately look for 'Table 1' (Baseline Characteristics). If the groups are not well-matched and the headline data is 'unadjusted', the results are almost always confounded.

Estimated Time:1m 15s

Question 4135Question →

A multicenter, randomized controlled trial evaluates the efficacy of a novel integrin antagonist versus placebo for inducing remission in patients with moderate-to-severe Crohn's disease. The primary endpoint is the rate of clinical remission at $14$ weeks. The initial unadjusted analysis yields a relative risk (RR) for clinical remission of $1.7$ ( $95\%$ CI: $1.3 - 2.2$ ) in the integrin antagonist group compared to the placebo group.

To further investigate the data, the researchers conduct a stratified analysis based on the patients' prior exposure to other biologic therapies (biologic-naïve vs. biologic-exposed). The results are summarized in the table below:

Patient Subgroup	Relative Risk ( $95\%$ CI)
Overall (Crude)	$1.7$ ( $1.3 - 2.2$ )
Biologic-naïve	$2.9$ ( $2.1 - 4.0$ )
Biologic-exposed	$1.0$ ( $0.6 - 1.5$ )

Based on these findings, which of the following statements provides the most accurate epidemiological interpretation of the stratified results?

The biological efficacy of the novel agent inherently varies depending on a patient's historical treatment profile.

An imbalance in historical treatment profiles between the drug and placebo groups artificially generated the overall association.

The lack of statistical significance in the previously exposed subgroup indicates the trial did not enroll enough participants to detect a true overall difference.

Subjective knowledge of the historical treatment profiles by the researchers likely skewed their assessments of clinical remission.

The historical treatment profile acts as a direct mechanistic intermediate in the pharmacological pathway of the novel agent.

Show answer & explanation

Answer: The biological efficacy of the novel agent inherently varies depending on a patient's historical treatment profile.

Answer

The data demonstrates that the new drug's efficacy inherently varies based on the patient's prior biologic exposure, representing effect modification.

The correct answer accurately describes the concept of effect modification without relying on standard terminology. The data shows that the integrin antagonist is highly effective in biologic-naïve patients (

RR = 2.9

) but provides no benefit over placebo in biologic-exposed patients (

RR = 1.0

). Because the true magnitude of the drug's effect differs across the strata of the third variable (prior exposure), this variable is an effect modifier. This represents a real biological interaction, not a statistical artifact.

Step-by-Step Solution

1

Analyze the crude relative risk (RR).

The overall RR is

1.7

, indicating a statistically significant positive association between the novel integrin antagonist and clinical remission.

Establishing the baseline association is necessary before evaluating the impact of stratification.

2

Compare the stratum-specific relative risks to each other and to the crude relative risk.

The RR in the biologic-naïve group is

2.9

, while the RR in the biologic-exposed group is

1.0

. These values are significantly different from each other.

Comparing stratum-specific RRs is the standard method to differentiate between confounding and effect modification.

3

Interpret the epidemiological phenomenon.

Because the effect size changes depending on the subgroup (stratum), the third variable (prior exposure) is an effect modifier, altering the true biological efficacy of the drug.

Effect modification is a natural biological phenomenon where the exposure-disease relationship varies across different levels of a third variable.

Key Concept

Effect modification occurs when the magnitude of an association between an exposure and an outcome differs significantly depending on the level of a third variable. Unlike confounding, it is not a flaw to be controlled, but a natural phenomenon to be reported.

Alternative Method

To quickly distinguish confounding from effect modification on the exam, remember the rule of 'S': If the Stratum-Specific relative risks are Similar to each other (but differ from the crude), it is confounding. If the Stratum-Specific relative risks are Significantly different from each other, it is effect modification.

Estimated Time:1m 15s

Question 4136Question →

An academic peer reviewer is evaluating the methodology section of a manuscript detailing a randomized, double-blind trial for a novel targeted biological therapy in severe eosinophilic asthma. The manuscript contains several specific methodological decisions and statistical observations. Match each excerpted description from the trial to the most accurate biostatistical or epidemiological concept it represents.

Click a left item, then click its matching right item

Show answer & explanation

Answer

The descriptions correctly match to: Exclusion of non-compliant patients matches Per-protocol analysis; Powering to retain 75% of active control effect matches Non-inferiority testing; Multivariate regression for baseline differences matches Confounding adjustment; Natural stabilization of extreme baseline values matches Regression to the mean.

Each excerpt distinctly defines a core epidemiological or biostatistical concept required for accurate medical literature interpretation: excluding non-compliers (per-protocol), testing against a margin (non-inferiority), correcting baseline differences (confounding adjustment), and observing natural normalization of extremes (regression to the mean).

Step-by-Step Solution

1

Analyze the handling of non-compliant patients in the first excerpt.

Removing patients missing a percentage of doses matches the concept of 'Per-protocol analysis'.

Per-protocol evaluates ideal efficacy by requiring adherence, unlike intention-to-treat which preserves original randomization.

2

Identify the study design based on the statistical power description and hypotheses.

Demonstrating retention of a specific percentage (75%) of the active control's effect matches 'Non-inferiority testing'.

This establishes a non-inferiority margin to prove the drug is not unacceptably worse than the current standard, rather than testing for strict superiority.

3

Evaluate the purpose of using multivariate regression to account for baseline imbalances.

Correcting for differing baseline corticosteroid use matches 'Confounding adjustment'.

Statistical adjustment is required when randomization fails to evenly distribute known confounding variables, ensuring the outcome difference is due to the drug.

4

Determine the statistical phenomenon occurring when extreme baseline symptoms improve naturally over time.

Natural stabilization after a peak exacerbation episode matches 'Regression to the mean'.

Extreme physiological measurements tend to normalize upon repeated measurement, which can be mistakenly attributed to a treatment effect if not carefully monitored.

Key Concept

Identifying methodological study designs, adjustments, and inherent statistical phenomena in medical literature

Estimated Time:1m 0s

Question 4137Question →

Match each epidemiological observation or clinical research scenario to the specific methodological concept, bias, or phenomenon it best illustrates.

Click a left item, then click its matching right item

Show answer & explanation

Answer

The scenarios correctly map to Recall bias (maternal memory differences), Effect modification (biologic efficacy differing by serostatus), Lead-time bias (increased survival time without mortality benefit), and Confounding by indication (antibiotic given to sicker patients), respectively.

Each scenario describes a specific, characteristic study flaw or finding. Scenario 1 describes unequal memory retrieval (Recall bias). Scenario 2 describes an intervention whose efficacy is dependent on a third variable, revealed by stratification (Effect modification). Scenario 3 describes early detection artifactually prolonging time-to-death metrics without changing disease progression (Lead-time bias). Scenario 4 describes a distortion where the baseline severity of disease dictates the intervention (Confounding by indication).

Step-by-Step Solution

1

Analyze the first scenario regarding mothers of infants with anomalies.

Identify that a negative outcome has prompted subjects to search their memory more thoroughly than controls.

This unequal memory retrieval distorts exposure data and defines Recall bias.

2

Examine the rheumatoid arthritis trial scenario involving stratified analysis.

Note that the third variable (serostatus) fundamentally changes the efficacy of the drug.

Because the effect differs across strata, this is a natural biological interaction known as Effect modification, distinct from confounding.

3

Evaluate the cancer screening scenario showing increased survival time but unchanged mortality.

Recognize that the disease was simply identified earlier in its natural course without changing the ultimate endpoint.

This artificial inflation of survival time is the hallmark of Lead-time bias.

4

Analyze the antibiotic observational study scenario.

Determine that patients given the new drug were systematically sicker (severe sepsis) than those given standard therapy.

The underlying severity of illness prompted the treatment choice and independently caused the higher mortality, which is Confounding by indication.

Key Concept

Accurately identifying and differentiating fundamental epidemiological biases and phenomena (Recall bias, Confounding by indication, Lead-time bias, Effect modification) in clinical research design.

Question 4138Question →

A clinical research group conducts a prospective cohort study to evaluate the efficacy of a newly approved monoclonal antibody targeting interleukin-5 (IL-5) compared to standard inhaled corticosteroid therapy in preventing severe asthma exacerbations. The primary outcome is the incidence of hospital admissions for asthma over a $12$ -month period.

The initial crude analysis reveals a relative risk (RR) of $0.65$ ( $95\%$ CI: $0.50-0.85$ ) for hospital admission in patients receiving the monoclonal antibody versus standard therapy.

To further investigate the data, the researchers perform a stratified analysis based on the patients' baseline absolute peripheral blood eosinophil counts. The results of the stratified analysis are as follows:

Patient Subgroup	Relative Risk	$95\%$ CI
Eosinophil count $< 300$ cells/µL	$0.98$	$0.82 - 1.15$
Eosinophil count $\ge 300$ cells/µL	$0.32$	$0.20 - 0.45$

Based on these statistical findings, which of the following best describes the epidemiological role of the baseline absolute eosinophil count in this study?

Effect modifier

Confounding variable

Dependent variable requiring analysis of variance

Determinant of negative predictive value

Incidental finding lacking clinical significance

Show answer & explanation

Answer: Effect modifier

Answer

Effect modifier

The correct answer is effect modifier. Effect modification (or interaction) occurs when the magnitude of an effect (such as relative risk or odds ratio) differs significantly between different strata of a third variable. In this scenario, the biologic therapy's efficacy is drastically different depending on the patient's baseline eosinophil count: there is no significant effect in patients with

< 300

cells/µL (as the

95\%

confidence interval crosses

1.0

), but there is a strong protective effect in those with

\ge 300

cells/µL. This biological interaction demonstrates that the baseline eosinophil count modifies the treatment effect of the drug.

Step-by-Step Solution

1

Identify the initial statistical finding from the crude analysis.

The crude relative risk (RR =

0.65

) suggests an overall protective effect of the monoclonal antibody.

Establishing the baseline overall effect is necessary before evaluating the impact of stratification.

2

Evaluate the results of the stratified analysis.

The RR in the low eosinophil group is

0.98

(no significant protective effect, as the CI crosses

1.0

), while the RR in the high eosinophil group is

0.32

(a very strong protective effect).

Comparing stratum-specific measures of association is the standard method for identifying interaction or confounding.

3

Apply the epidemiological definitions of confounding and effect modification.

Because the measure of association differs significantly between the two strata, the stratifying variable (eosinophil count) represents effect modification.

Effect modification describes a biological or physical interaction where the exposure's effect on the outcome genuinely differs across levels of a third variable.

Key Concept

Effect modification is present when the magnitude of an association between an exposure and an outcome differs significantly according to the level of a third variable (the effect modifier).

Question 4139Question →

A 42-year-old construction worker is brought to the emergency department by paramedics after falling approximately 25 feet from a scaffold. The patient is immobilized on a backboard with a rigid cervical collar in place. He is obtunded, and pooling of blood and secretions is visible in his oropharynx. Vital signs are temperature 36.2°C (97.2°F), blood pressure 72/40 mmHg, pulse 142/min, and respirations 36/min. Pulse oximetry shows 84% on a 15-L nonrebreather mask. Physical examination reveals a Glasgow Coma Scale score of 7 (E2, V2, M3). His trachea is deviated to the right. There are absent breath sounds over the left hemithorax and hyperresonance to percussion. Jugular venous distention is present. His abdomen is distended and firm. Bilateral large-bore peripheral intravenous access is immediately established by nurses. Arrange the following management steps in the most appropriate chronological order.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence strictly follows the Advanced Trauma Life Support (ATLS) primary survey algorithm (ABCDE): secure the Airway, decompress the left chest for Breathing, administer blood products for Circulation, perform a FAST exam as an adjunct, and finally transport for CT imaging once stabilized.

In severe polytrauma, management must strictly adhere to the ABCDE algorithm. This patient presents with multiple immediate life threats. His GCS of 7 and pooled secretions mandate intubation (Airway). His rightward tracheal deviation and absent left breath sounds indicate a tension pneumothorax, requiring immediate decompression (Breathing). His profound hypotension and distended abdomen suggest hemorrhagic shock, requiring blood products (Circulation). Only after these ABCs are addressed should bedside diagnostics like the FAST exam be performed. Finally, transport for CT scanning is strictly reserved for patients who have been hemodynamically stabilized; transporting an unstable patient risks cardiac arrest outside the resuscitation bay.

Step-by-Step Solution

1

Secure the airway with endotracheal intubation.

The airway is protected from aspiration and oxygenation can be mechanically supported.

A GCS less than 8 and pooled secretions indicate airway failure, which is the most immediate threat to life (Airway).

2

Decompress the left hemithorax with a needle or finger thoracostomy.

Intrathoracic pressure decreases, allowing the mediastinum to shift back to midline and venous return to the heart to resume.

The patient has a tension pneumothorax causing obstructive shock, which must be managed immediately after securing the airway (Breathing).

3

Initiate massive transfusion with uncrossmatched blood.

Intravascular volume and oxygen-carrying capacity begin to be restored.

With the obstructive shock relieved, hemorrhagic shock from the likely intra-abdominal injury must be addressed (Circulation).

4

Perform a FAST exam.

Rapid identification of intra-abdominal hemorrhage or pericardial effusion is achieved.

This is the primary diagnostic adjunct to the ABCs to guide the necessity for emergency laparotomy.

5

Transport to the CT scanner.

Detailed anatomical evaluation of injuries is obtained.

Advanced imaging is part of the secondary survey and is contraindicated until the patient's airway, breathing, and hemodynamics are stabilized.

Key Concept

Advanced Trauma Life Support (ATLS) sequential prioritization: Airway, Breathing, Circulation, Disability, Exposure (ABCDE), followed by adjunct diagnostics and secondary survey imaging.

Question 4140Question →

Public health researchers are investigating the cardiovascular safety of a widely used electronic vaping device. In an initial, unadjusted analysis of an observational cohort containing 15,000 adults, the researchers calculate a relative risk of 2.2 (95% CI: 1.6 - 3.0) for the development of incident coronary artery disease among daily users of the device compared to non-users.

Suspecting that other behavioral factors might be influencing the results, the research team performs a secondary analysis stratified by a history of traditional combustible cigarette smoking. In the stratified analysis, the relative risk for coronary artery disease among vaping device users is 1.06 (95% CI: 0.8 - 1.3) in those with a history of smoking, and 1.04 (95% CI: 0.7 - 1.4) in those without a history of smoking.

Based on these findings, which of the following best characterizes the role of traditional cigarette smoking in this study?

It is associated with both the exposure and the outcome but does not lie on the causal pathway.

It biologically alters the magnitude of the exposure's effect, demonstrating true stratum-specific differences.

It indicates that the investigators should have utilized an analysis of variance rather than relative risk calculations.

It shifts the predictive values of the diagnostic studies by altering the baseline prevalence of the disease.

It represents a clinical distractor that leads to the overinterpretation of transient, mild laboratory abnormalities.

Show answer & explanation

Answer: It is associated with both the exposure and the outcome but does not lie on the causal pathway.

Answer

Traditional cigarette smoking acts as a confounding variable because it is associated with both the exposure (vaping) and the outcome (coronary artery disease) without being in the causal pathway.

The correct answer identifies traditional cigarette smoking as a confounding variable. A confounder is an extraneous factor that correlates with both the independent variable (vaping) and the dependent variable (coronary artery disease) but does not lie on the causal pathway between them. In this scenario, individuals who vape are more likely to have a history of traditional smoking, and traditional smoking is an independent cause of coronary artery disease. When the researchers performed a stratified analysis to isolate the groups, the relative risk of coronary artery disease among vaping users dropped to near 1.0 in both strata (confidence intervals 0.8 - 1.3 and 0.7 - 1.4). Because the initial significant association disappeared once the data were separated by smoking status, it is clear that smoking was responsible for the spurious unadjusted relative risk of 2.2.

Step-by-Step Solution

1

Analyze the unadjusted study results.

The initial relative risk is 2.2, suggesting a significant association between vaping and coronary artery disease.

Establishing the baseline finding is necessary before interpreting the effect of stratification.

2

Evaluate the results after stratifying by the suspected variable (smoking).

The relative risks in both strata (1.06 and 1.04) are approximately 1.0, and the confidence intervals cross 1.0.

Stratification is a primary method used to distinguish between confounding and effect modification.

3

Interpret the change in risk.

Because the association disappears upon stratification, the initial relationship was spurious and driven by smoking status.

This behavior perfectly matches the definition of a confounder, not an effect modifier.

Key Concept

In epidemiological studies, confounding occurs when a variable is associated with both the exposure and the outcome but is not on the causal pathway, leading to a spurious association that disappears upon stratification.

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Alternative Method

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Alternative Method

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer